Our perspectives
in one place
Topic
Selected filters
ClearNews
See allBiopharmaceutical CEOs Roundtable met in Berlin
12 NOVEMBER 2025, Berlin – The Biopharmaceutical CEOs Roundtable (BCR), a global policy platform representing the world’s leading biopharmaceutical companies, convened last week in Berlin to discuss how pharmaceutical innovation can drive better health outcomes, strengthen economies, and enhance global health security. The BCR delegation also met with Federal Chancellor Merz, along with key members...
Read moreWIPO Standing Committee on Patents (SCP 37): Technology Transfer
On 5 November 2025, IFPMA delivered a statement on technology transfer at the WIPO Standing Committee on Patents (SCP 37) in Geneva. Technology transfer in the pharmaceutical sector is a complex and resource-intensive process. It requires significant technical expertise, time, and investment, as well as a robust, stable, and predictable intellectual property framework, which is...
Read moreWIPO Standing Committee on Patents (SCP 37): Patents and health
On 4 November 2025, IFPMA delivered a statement on patents and health at the WIPO Standing Committee on Patents (SCP 37) in Geneva. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents the global research-based biopharmaceutical industry. We appreciate the opportunity to address the Committee on patents and health. Intellectual property is fundamental to...
Read moreStatement on PABS Instrument at the third meeting of the open-ended Intergovernmental Working Group (IGWG 3) on the WHO Pandemic Agreement
On 3 November 2025 in Geneva, IFPMA delivered a statement at at the tnird meeting of the open-ended Intergovernmental Working Group (IGWG 3) on the WHO Pandemic Agreement.
Read more75th WHO Regional Committee for Europe on the Action Plan for the Prevention and Control of Noncommunicable Diseases in the WHO European Region 2016–2025
On 30 October 2025 at the 75th WHO Regional Committee for Europe, IFPMA, together with European member association EFPIA, submitted a statement on the Action Plan for the Prevention and Control of Noncommunicable Diseases in the WHO European Region 2016-2025. This statement is delivered on behalf of IFPMA and its European member organization EFPIA. We...
Read more76th Session of the WHO Regional Committee for the Western Pacific on “Implementing the International Health Regulations (2005) amendments”
On 21 October 2025 in Nadi, Fiji, IFPMA delivered a statement at the 76th Session of the WHO Regional Committee for the Western Pacific on “Implementing the International Health Regulations (2005) amendments.” We commend the Western Pacific Region for its engagement to develop priority actions for countries and areas in the region to utilize the...
Read morePublications
See allPolicy considerations for the development, regulation and adoption of biosimilars
Biosimilars can play a role in expanding patient access to biological medicines and in supporting the sustainability of healthcare systems. To fully realize this potential, IFPMA recommends the adoption of a series of policy recommendations.
Read moreAdult immunization: A critical investment for health, equity, and economic resilience
Immunization is an effective public health strategy to help prevent and reduce the impact of infectious diseases throughout the life course. As populations age and non-communicable diseases (NCDs) increase, our societies are becoming more vulnerable to preventable infectious diseases. This can put a significant strain on health systems, societies, and economies. Vaccines are wide recognized...
Read more
Revitalizing the antibiotic pipeline by implementing new R&D pull incentives
With the 2024 UN High-Level Meeting on antimicrobial resistance (AMR) and its political declaration, together with the biennial AMR Ministerial Meeting, the world has set an ambitious agenda to tackle AMR. The next four years offer renewed political momentum to deliver progress ahead of the next UN High-Level Meeting on AMR in 2029. A central priority is creating the necessary policy frameworks that stimulate R&D investment. This brief identifies the key barriers to antibiotic R&D and the policy measures needed to address them. Sustainable, effective pull incentives are urgently required to ensure a reliable pipeline of new antibiotics for patients and health systems. We set out how these incentives should be designed and implemented, guided by a set of core principles to maximize their impact.
Read more
Expert insights
See all
Getting procurement right: sustainable and secure supply chains that support access to medicines
Read more
G7 Canada is an opportunity to unlock the potential of life sciences
Read more
Global resilience and national security starts with preventing ill health
Read moreResources
See allStreamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more
Our Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more